Table 1 Baseline characteristics and clinical outcomes of patients
| Â | LZD group | Â | LZD/RFP group | Â |
|---|---|---|---|---|
Gender (male/female) | 4 / 3 | Â | 2 / 1 | Â |
Age (year) | 60 ± 19 | [21–82] | 51 ± 11 | [41–62] |
Body weight (kg) | 66.0 ± 17.2 | [46.6–95.0] | 57.8 ± 14.5 | [46.0–74.0] |
eGFR (mL/min/1.73 m2) | 65.2 ± 26.3 | [32.7–105] | 99.9 ± 34.7 | [65.6–135] |
Baseline CRP concentration (mg/dL) | 3.0 ± 3.1 | [0.7–8.9] | 1.8 ± 0.6 | [1.2–2.4] |
LZD dose and concentrations | ||||
 Total dose (g) | 14.3 ± 5.2 | [7.2–21.0] | 28.4 ± 9.1 | [18.0–34.8] |
 Daily dose (g/day) | 1.04 ± 0.21 | [7.29–1.20] | 1.20 ± 0.0 |  |
 Daily dose (mg/kg/day) | 16.7 ± 5.7 | [10.5–25.8] | 21.6 ± 5.0 | [16.2–26.1] |
 Duration of LZD therapy (day) | 14 ± 6 | [6–21] | 24 ± 8 | [15–29] |
 Number of TDM | 21 |  | 13 |  |
 Trough concentration at first assessment day (μg/mL) | 13.3 ± 8.4 | [4.7–29.4] | 6.9 ± 5.0 | [2.1–12.1] |
 C/D ratio at first assessment day (μg/mL/mg/kg/day) | 0.83 ± 0.46 | [0.32–1.34] | 0.29 ± 0.17 | [0.13–0.47] |
 Patients with dosage adjustments to avoid overexposure, n (%) | 3 (42.9%) |  | 0 (0%) |  |
CRP concentration at first assessment day (mg/dL) | 4.2 ± 4.6 | [0.3–13.8] | 2.0 ± 2.0 | [0.7–4.3] |
Hematological adverse effects | ||||
 Baseline platelet count (106 platelets/μL) | 266 ± 88 | [174–445] | 325 ± 128 | [189–443] |
 Nadir platelet count (106 platelets/μL) | 150 ± 82 | [86–320] | 173 ± 113 | [69–293] |
 Thrombocytopenia, n (%) | 4 (57.1%) |  | 1 (33.3%) |  |
 Baseline Hb (g/dL) | 9.6 ± 1.8 | [7.3–12.9] | 11.4 ± 1.2 | [10.1–12.2] |
 Nadir Hb (g/dL) | 8.9 ± 2.2 | [6.8–12.8] | 10.4 ± 2.8 | [7.1–12.1] |
 Anemia, n (%) | 3 (42.9%) |  | 1 (33.3%) |  |
Outcomes | ||||
 Success, n (%) | 5 (71.4%) |  | 3 (100%) |  |